Martin Rabe

1.1k total citations · 1 hit paper
30 papers, 825 citations indexed

About

Martin Rabe is a scholar working on Physiology, Industrial and Manufacturing Engineering and Computational Theory and Mathematics. According to data from OpenAlex, Martin Rabe has authored 30 papers receiving a total of 825 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 7 papers in Industrial and Manufacturing Engineering and 5 papers in Computational Theory and Mathematics. Recurrent topics in Martin Rabe's work include Alzheimer's disease research and treatments (9 papers), Computational Drug Discovery Methods (5 papers) and Digital Transformation in Industry (5 papers). Martin Rabe is often cited by papers focused on Alzheimer's disease research and treatments (9 papers), Computational Drug Discovery Methods (5 papers) and Digital Transformation in Industry (5 papers). Martin Rabe collaborates with scholars based in Germany, United States and United Kingdom. Martin Rabe's co-authors include Shobha Dhadda, Jinping Wang, Jeffrey L. Cummings, Lynn D. Kramer, Chad J. Swanson, June Kaplow, Robert J. Gordon, Heather Bradley, Larisa Reyderman and Robert Lai and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Neurology.

In The Last Decade

Martin Rabe

27 papers receiving 809 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

2021 580 citations Chad J. Swanson, Yong Zhang et al. Alzheimer s Research & Therapy profile →

Peers

Countries citing papers authored by Martin Rabe

Since Specialization

Citations

This map shows the geographic impact of Martin Rabe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Rabe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Rabe more than expected).

Fields of papers citing papers by Martin Rabe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Rabe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Rabe. The network helps show where Martin Rabe may publish in the future.

Co-authorship network of co-authors of Martin Rabe

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Rabe. A scholar is included among the top collaborators of Martin Rabe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Rabe. Martin Rabe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Venture Clienting in Corporate Practice: What type of Established Companies are Using the Venture Client Model? 2024 ·Fraunhofer-Publica (Fraunhofer-Gesellschaft) ·(unknown), (unknown), (unknown), Martin Rabe, Arno Kühn, Roman Dumitrescu	0
2	Venture Client Model: A systematic Literature Review 2023 ·(unknown), (unknown), Martin Rabe, (unknown), Roman Dumitrescu	1
3	Data-Driven Product Management: A Practitioner-Driven Research Agenda 2023 ·Procedia CIRP ·(unknown), (unknown), (unknown), Martin Rabe, (unknown), Arno Kühn, Roman Dumitrescu, (unknown)	3
4	Trial in Progress: An Open-Label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 in Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria 2022 ·Blood ·(unknown), Bing Han, Guangsheng He, Hu Zhou, Chunrong Wang, (unknown), (unknown), Martin Rabe, Helen Fu, (unknown), Ping Tsui, Jing‐Tao Wu, Frederick C. Beddingfield, Wenru Song, Richard Lee	0
5	Data-Driven Model for Upper Limb Spasticity Detection 2021 ·International Journal of Integrated Engineering ·(unknown), Cheng-Yaw Low, (unknown), Fazah Akhtar Hanapiah, (unknown), (unknown), (unknown), Martin Rabe, (unknown), (unknown), (unknown), Roman Dumitrescu, (unknown)	1
6	BASELINE CHARACTERISTICS FOR CLARITY-AD: A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 18-MONTH STUDY EVALUATING BAN2401 IN EARLY ALZHEIMER’S DISEASE (3021) 2021 ·Neurology ·(unknown), Michael C. Irizarry, Shobha Dhadda, Tanya Bogoslovsky, Larisa Reyderman, June Kaplow, Martin Rabe, Lynn D. Kramer, Harald Hampel, Chad J. Swanson	1
7	A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody breakdown → 2021 ·Alzheimer s Research & Therapy ·Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert J. Gordon, Lynn D. Kramer, Jeffrey L. Cummings	580
8	Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease 2021 ·Alzheimer s & Dementia ·(unknown), Michael C. Irizarry, Shobha Dhadda, (unknown), Michio Kanekiyo, Tanya Bogoslovsky, Michelle Gee, Larisa Reyderman, June Kaplow, Martin Rabe, (unknown), Lynn D. Kramer, Harald Hampel, Chad J. Swanson	2
9	Lecanemab, an anti-Aβ protofibril antibody: Updated data from a randomized, double-blind phase 2B proof of concept clinical trial and open-label extension in early Alzheimer's disease 2021 ·Journal of the Neurological Sciences ·Chad J. Swanson, Shobha Dhadda, (unknown), David Li, Michio Kanekiyo, June Kaplow, Martin Rabe, (unknown), Robert J. Gordon, Robert Lai, Lynn D. Kramer, Larisa Reyderman	2
10	AHEAD 3‐45 study: Preliminary screening and baseline characteristics from a placebo‐controlled, double‐blind study evaluating lecanemab in participants with preclinical Alzheimer’s disease and elevated (A45 trial) and intermediate (A3 trial) amyloid 2021 ·Alzheimer s & Dementia ·(unknown), Michael C. Irizarry, Lynn D. Kramer, Chad J. Swanson, Claire Roberts, Shobha Dhadda, (unknown), Martin Rabe, (unknown), Rema Raman, Michael Donohue, Gopalan Sethuraman, Keith A. Johnson, Reisa A. Sperling, Paul Aisen	1
11	A preliminary assessment of longitudinal amyloid status in the ongoing open‐label extension phase in subjects with early Alzheimer’s disease 2020 ·Alzheimer s & Dementia ·Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Heather Bradley, Martin Rabe, Robert Lai, Robert J. Gordon, Lynn D. Kramer	1
12	Persistence Of BAN2401-Mediated Amyloid Reductions Post-treatment: A Preliminary Comparison of Amyloid Status Between the Core Phase of BAN2401-G000-201 and Baseline of the Open-Label Extension Phase in Subjects with Early Alzheimer’s Disease (1330) 2020 ·Neurology ·Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Heather Bradley, Martin Rabe, (unknown), Robert Lai, Robert J. Gordon, Lynn D. Kramer	9
13	Data Science Platform for Smart Diagnosis of Upper Limb Spasticity 2020 ·Procedia Manufacturing ·(unknown), Cheng Yee Low, (unknown), (unknown), Martin Rabe, (unknown), (unknown), Fazah Akhtar Hanapiah, (unknown), (unknown)	2
14	AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial) 2020 ·Alzheimer s & Dementia ·Paul Aisen, (unknown), Michael C. Irizarry, Lynn D. Kramer, Chad J. Swanson, Shobha Dhadda, Martin Rabe, (unknown), (unknown), Rema Raman, Michael Donohue, Gopalan Sethuraman, Keith A. Johnson, Reisa A. Sperling	17
15	DT‐01‐01: BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY 2019 ·Alzheimer s & Dementia ·José Luís Molinuevo, Akihiko Koyama, Shobha Dhadda, Michael C. Irizarry, Chad J. Swanson, Yong Zhang, June Kaplow, Heather Bradley, Martin Rabe, (unknown), Robert Lai, Robert J. Gordon, Lynn D. Kramer	2
16	Smart Factory Reference Model for Training on Industry 4.0 2019 ·Journal of Mechanical Engineering ·(unknown), Cheng Yee Low, (unknown), (unknown), (unknown), Roman Dumitrescu, Martin Rabe, (unknown), (unknown)	4
17	Smart Services – Konzept einer neuen Marktleistung 2018 ·Zeitschrift für wirtschaftlichen Fabrikbetrieb ·(unknown), (unknown), Martin Rabe, Roman Dumitrescu, Jürgen Gausemeier, Arno Kühn	7
18	Systematic Development of Smart Factory using CONSENS 2018 ·Procedia Manufacturing ·(unknown), Cheng Yee Low, (unknown), (unknown), Martin Rabe, Roman Dumitrescu, (unknown)	1
19	Framework for the agile development of innovative Product-Service-Systems for existing physical rehabilitation systems 2018 ·Procedia Manufacturing ·(unknown), Martin Rabe, Cheng Yee Low, (unknown), Arno Kühn, Roman Dumitrescu	9
20	ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials 2016 ·Journal of Neurology Neurosurgery & Psychiatry ·Jinping Wang, Veronika Logovinsky, Suzanne Hendrix, (unknown), Carlos Perdomo, Lu Xu, Shobha Dhadda, (unknown), Martin Rabe, Johan Luthman, Jeffrey L. Cummings, Andrew Satlin	115

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact